Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Nanoviricides Inc. (NNVC:NYSE), powered by AI.
Nanoviricides Inc. is currently trading at $1.36. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Nanoviricides Inc. on Alpha Lenz.
Nanoviricides Inc.'s P/E ratio is -2.2.
“Nanoviricides Inc. trades at a P/E of -2.2 (undervalued) with modest ROE of -99.7%.”
Ask for details →Nanoviricides Inc. is a pioneering biotechnology company that focuses on the development of therapeutics to combat viral infections using nanotechnology. The company is dedicated to creating antiviral nanomedicine known as "nanoviricides," which are designed to specifically attack and neutralize virus particles. This innovative approach allows Nanoviricides Inc. to target a wide range of viruses effectively and with precision. The central aim of Nanoviricides Inc. is to address unmet medical needs, particularly in treating viral diseases for which there are limited or no effective treatments available. The biotechnology sector heavily influences its operations, placing it at the cutting edge of medical and scientific advancement. Its products have the potential to serve critical roles in healthcare, particularly in infectious disease control. Nanoviricides Inc.'s work is significant within the pharmaceutical and healthcare industries as it embodies the growing trend towards precision medicine and personalized healthcare solutions. By leveraging nanotechnology, Nanoviricides Inc. aims to make substantial contributions to public health and play a vital role in future pandemics and viral outbreak responses.
“Nanoviricides Inc. trades at a P/E of -2.2 (undervalued) with modest ROE of -99.7%.”
Ask for details →Nanoviricides Inc. (ticker: NNVC) is a company listed on NYSE in the Healthcare sector (Biotechnology). It has approximately 7 employees. Market cap is $21M.
The current price is $1.36 with a P/E ratio of -2.17x and P/B of 2.73x.
ROE is -99.75%.